EP2827862
Samsetningar af bendamústíni
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
15.3.2013EP published:
27.12.2023EP application number:
13764989.3
EP translation filed:
29.1.2024Grant published:
15.2.2024EPO information:
European Patent Register
Max expiry date:
14.3.2033Expiry date:
14.3.2027Next due date:
31.3.2027
Title in English:
FORMULATIONS OF BENDAMUSTINELanguage of the patent:
English
Timeline
Today
15.3.2013EP application
27.12.2023EP Publication
29.1.2024Translation submitted
15.2.2024Registration published
14.3.2027Expires
Owner
Name:
Eagle Pharmaceuticals, Inc.Address:
50 Tice Boulevard Suite 315, Woodcliff Lake, NJ 07677, US
Inventor
Name:
SUNDARAM, SrikanthAddress:
Somerset, New Jersey 08873, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261613173 PDate:
20.3.2012Country:
US
Number:
201261669889 PDate:
10.7.2012Country:
US
Classification
Categories:
A61K 31/4184, A61K 47/10, A61K 47/20, A61K 9/00
Annual fees
Number
Paid
Expires
Payer
Number: 12
Paid: 28.2.2024
Expires: 14.3.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 11.2.2025
Expires: 14.3.2026
Payer: Árnason Faktor ehf.
Number: 14
Paid: 12.3.2026
Expires: 14.3.2027
Payer: Árnason Faktor ehf.